K
Kaigene
United States · Biotech
Kaigene develops antibody medicines for autoimmune diseases, targeting harmful antibodies and the cells that produce them.
Platforms
The company develops antibody discovery platforms and therapeutic programs aimed at modifying disease mechanisms. Its pipeline includes FcRn and APRIL targeted candidates.
Development
Kaigene is based in Rockville, Maryland. Its research and licensing partnerships support the development of medicines for severe autoimmune conditions.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Equity offering | $55M | Participants not disclosed |